AssetMark Inc’s Sage Therapeutics SAGE Stock Holding History

AssetMark Inc’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-81,946	Closed	-$3.63M	–	1629
2021 Q3	$3.63M	Buy	+81,946	New	+$3.76M	0.02%	282

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AssetMark Inc's SAGE Position: Q4 2021 in Review

AssetMark Inc sold out of Sage Therapeutics (SAGE) in Q4 2021, closing a stake of 81,946 shares — an estimated $3.63M sold.

AssetMark Inc first reported a position in SAGE in Q3 2021 and held it in 1 quarter. The position peaked at $3.63M in Q3 2021. 216 funds tracked by Wall St. Rank hold SAGE as of Q4 2021.

AssetMark Inc reported no remaining Sage Therapeutics position as of Q4 2021 after selling out during the quarter.
AssetMark Inc sold 81,946 Sage Therapeutics shares in Q4 2021, an estimated $3.63M.
AssetMark Inc first reported a position in Sage Therapeutics in Q3 2021 and held it in 1 quarter.
AssetMark Inc's Sage Therapeutics position peaked at $3.63M in Q3 2021.
216 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2021.

Based on AssetMark Inc's 13F filing for Q4 2021, filed 14 Feb 2022.